Results 61 to 70 of about 658,116 (357)
Serum Epidermal Growth Factor in Cancer Breast
Journal of High Institute of Public Health, 2007 Several prognostic factors are evaluated in the breast carcinoma and there is a need for new markers for better discrimination of the biologic differences in the primary tumor.
El-Attar HA +3 more
doaj +1 more source
Thoracic Cancer, 2021 Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi +10 more
doaj +1 more source
Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage [PDF]
, 2018 Chronickidneydisease (CKD)ischaracterized bypersistent inflammationandprogressive fibrosis,ultimatelyleadingto end-stage renal disease. Although many studies have investigated the factors involved in the progressive deterioration of renal function, current
Goldschmeding, Roel +6 more
core +2 more sources
Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers
Molecular Oncology, EarlyView.This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel +6 more
wiley +1 more source
Tumor Biology, 2017 Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are first-choice treatments for advanced non-small-cell lung cancer patients harboring EGFR mutations.
Huang-Chih Chang +9 more
doaj +1 more source
Novel role for amphiregulin in protection from liver injury [PDF]
, 2005 Clinically, the Fas and Fas ligand system plays a central role in the development of hepatocyte apoptosis, a process contributing to a broad spectrum of liver diseases.
Avila, M.A. (Matías Antonio) +7 more
core
Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? [PDF]
, 2008 PURPOSE OF REVIEW: The recent advances in the use of targeted therapy in pancreatic cancer are based on the knowledge of genetic alterations that occur during pancreatic carcinogenesis.
Laurent-Puig, Pierre, Taieb, Julien
core +2 more sources
Molecular Oncology, EarlyView.Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova +25 more
wiley +1 more source
COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells
Molecular Oncology, EarlyView.This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos +6 more
wiley +1 more source
Molecular Oncology, EarlyView.Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau +36 more
wiley +1 more source